Company profile: Juno Therapeutics

1.1 - Company Overview

Juno Therapeutics

Headquarter: United States

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of clinical-stage immunotherapies for the treatment of cancer, formed through a unique partnership with Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children’s Research Institute to advance a broad pipeline of breakthrough immunotherapies.

Products and services

🔒

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to Juno Therapeutics

Acepodia

HQ: United States Website

Description: Provider of cancer cell therapies and platform technology, including ACC (Antibody-Cell Conjugation) to attach tumor-targeting antibodies to immune cells without genetic engineering; off-the-shelf allogeneic γδ2 T cell therapies; and ACC-γδ2 T cell candidates ACE1831 (CD20), ACE2016 (EGFR), and ACE1708 (PD-L1).

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Acepodia company profile →

Intact Medical

HQ: United States Website

Description: Provider of minimally invasive systems for volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Intact Medical company profile →

CASI Pharmaceuticals

HQ: United States Website

Description: Provider of business development aimed at building a pipeline through mutually beneficial transactions.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full CASI Pharmaceuticals company profile →

Therapeutic Solutions International

HQ: United States Website

Description: Provider of biotechnology therapies and nutraceuticals, including JadiCell mesenchymal stem cell therapy for COVID-19 lung injury, COPD, and CTE; QuadraMune to enhance natural killer cell activity and immune support; StemVacs and StemVacs-V cancer immunotherapies; CampbellCell for psychiatric diseases; and FloraStilbene as an immunotherapy adjuvant.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Therapeutic Solutions International company profile →

NMS Group

HQ: Italy Website

Description: Provider of oncology research and development, managing the integrated R&D chain from pre-clinical to clinical stages. Operates a validated oncology drug discovery platform generating a pipeline of new chemical entities (NCEs).

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full NMS Group company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for Juno Therapeutics

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Juno Therapeutics

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in Juno Therapeutics's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in Juno Therapeutics's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to Juno Therapeutics

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in Juno Therapeutics's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in Juno Therapeutics's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Juno Therapeutics

4.2 - Public trading comparable groups for Juno Therapeutics

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Juno Therapeutics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Juno Therapeutics

What does Juno Therapeutics do?

Juno Therapeutics is a provider of clinical-stage immunotherapies for the treatment of cancer, formed through a unique partnership with Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children’s Research Institute to advance a broad pipeline of breakthrough immunotherapies.

Who are Juno Therapeutics's competitors?

Juno Therapeutics's competitors and similar companies include Acepodia, Intact Medical, CASI Pharmaceuticals, Therapeutic Solutions International, and NMS Group.

Where is Juno Therapeutics headquartered?

Juno Therapeutics is headquartered in United States.

How many employees does Juno Therapeutics have?

Juno Therapeutics has 1,000 employees 🔒.

When was Juno Therapeutics founded?

Juno Therapeutics was founded in 2010 🔒.

What sector and industry vertical is Juno Therapeutics in?

Juno Therapeutics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Juno Therapeutics

Who are the top strategic acquirers in Juno Therapeutics's sector and industry

Top strategic M&A buyers and acquirers in Juno Therapeutics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Juno Therapeutics?

Top strategic M&A buyers groups and sectors for Juno Therapeutics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Juno Therapeutics's sector and industry vertical

Which are the top PE firms investing in Juno Therapeutics's sector and industry vertical?

Top PE firms investing in Juno Therapeutics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Juno Therapeutics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Juno Therapeutics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Juno Therapeutics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Juno Therapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Juno Therapeutics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Juno Therapeutics?

The key public trading comparables and valuation benchmarks for Juno Therapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Juno Therapeutics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Juno Therapeutics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Juno Therapeutics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Juno Therapeutics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Juno Therapeutics's' sector and industry vertical?

Access recent funding rounds and capital raises in Juno Therapeutics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Juno Therapeutics

Start Free Trial Book a Demo